New cocktail of drugs shows promise against tough blood cancer

NCT ID NCT06068621

Completed Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of six drugs (venetoclax plus CACAG regimen) against the standard '3+7' chemotherapy in 200 adults newly diagnosed with acute myeloid leukemia. The goal was to see if the new combo leads to more complete remissions after one treatment course. The trial is complete, and results will show whether this approach is more effective and safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax combined with azacytidine, cytarabine, aclacinomycin, chidamide, and granulocyte colony-stimulating factor
What this could lead to: If successful, this combination could offer a more effective first-line treatment option for acute myeloid leukemia, potentially improving remission rates.
What could go wrong: This is a Phase 2 trial, so results are preliminary. The combination may cause more side effects than standard therapy, and it is not yet proven to be better or safer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.